AbbVie hikes full-year earnings guidance as Humira sales top estimates

Abbvie (ABBV) PT Raised to $200 at Goldman Sachs

Goldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a Buy rating.

The analyst comments "Even amidst expectations that Immunology would once again deliver, we see basis for the factors underpinning growth for both Skyrizi and Rinvoq to continue propelling upside - including NBRx dynamics that... More

William Blair Reiterates Outperform Rating on Abbvie (ABBV)

William Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).

The analyst comments "Stock thoughts: We believe AbbVie has a strong and durable growth profile over the coming years thanks to its strong growth platform, recently augmented by the... More

Abbvie (ABBV) PT Raised to $210 at Truist Securities

Truist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $195.00) while maintaining a Buy rating.

The analyst comments "ABBV reported strong 2Q24 results with top and bottom line beats, led by Skyrizi/RInvoq. Given the share... More

Abbvie (ABBV) PT Raised to $210 at JPMorgan

JPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight rating.

The analyst comments "Exiting 2Q results, we our updating our model and wanted to share our key changes. Overall, we are increasing our estimates to... More

AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.65, $0.05 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.02 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $10.71-$10.91, versus the consensus of $10.90.

For earnings history and earnings-related data on AbbVie (ABBV) click here.